Anticipated $-0.64 EPS for Zynerba Pharmaceuticals, Inc. (ZYNE) as of May, 8

Marco Green
April 17, 2018

Centurylink Inc now has $18.40 billion valuation. Its shares touched $10.02 on during the last trading session after 1.47% change.Zynerba Pharmaceuticals, Inc. has volume of 159,528 shares. About 32.05 million shares traded or 35.83% up from the average. CenturyLink, Inc. (NYSE:CTL) has declined 28.66% since April 16, 2017 and is downtrending. On Monday, September 14 the stock rating was initiated by Canaccord Genuity with "Buy". They now have a $23.0000 target price per share on the stock. Through this figure traders can analyze that ZYNE show whether or not a stock now most active and standing in buying side or sell side. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. Therefore 100% are positive. (ZYNE) recently traded -19.89% away from the 50-day high and moved 29.06% from the 50-day low. (NASDAQ:ZYNE)'s earnings report, Zacks reports. The firm has "Overweight" rating given on Monday, August 31 by Piper Jaffray. Zynerba Pharmaceuticals earned a daily sentiment score of 0.15 on Accern's scale.

Among 6 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 6 have Buy rating, 0 Sell and 0 Hold. The rating was maintained by UBS with "Sell" on Thursday, September 15. The rating was upgraded by BNP Paribas on Wednesday, May 11 to "Outperform". Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday, February 1st.

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. Cantor Fitzgerald has "Buy" rating and $17.0 target. The firm's market capitalization is $224.74 million. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. It now has negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, August 2014.

The stock increased 2.73% or $0.27 during the last trading session, reaching $10.17.

Among 6 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 6 have Buy rating, 0 Sell and 0 Hold. The stock underperformed the S&P500 by 71.43%. Analysts at Wall Street see Zynerba Pharmaceuticals, Inc.'s 6.67 % negative EPS growth compared to $-0.60 earnings per share for last quarter. They expect $0.68 EPS, up 3.03% or $0.02 from last year's $0.66 per share. Therefore 41% are positive. Finally, Seaport Global Securities began coverage on shares of Zynerba Pharmaceuticals in a report on Friday, January 26th. The stock of CenturyLink, Inc. Jefferies has "Hold" rating and $22.0 target. Oppenheimer initiated the stock with "Outperform" rating in Tuesday, September 8 report. The firm has "Neutral" rating given on Monday, April 4 by Nomura. The firm earned "Market Perform" rating on Monday, October 16 by BMO Capital Markets. (NYSE:CTL) rating on Thursday, November 9. J.P. Morgan has "Buy" rating and $26.0 target. 375,427 were reported by Deutsche State Bank Ag. Brown Brothers Harriman invested in 16.77 million shares or 5.59% of the stock. Fleetcor Technologies Inc (NYSE:FLT) was reduced too. Its down 0.98, from 2 in 2017Q3. 44 funds opened positions while 61 raised stakes. Canada Pension Plan Invest Board stated it has 79,500 shares. Scotia Cap reported 0.01% stake. Sumitomo Mitsui Trust has invested 0.06% in CenturyLink, Inc.

A number of equities analysts have issued reports on ZYNE shares. Acadian Asset Management Llc reported 74,967 shares stake. Vantage Ltd Liability Co reported 519 shares. Rathbone Brothers Public Ltd Company invested in 0.15% or 60,092 shares. (NYSE:CTL) for 33,964 shares. St Germain D J holds 150,871 shares or 1.09% of its portfolio. Great West Life Assurance Can accumulated 10,485 shares.

Other reports by Click Lancashire

Discuss This Article